Clinical trial
A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy
NCT02979561 is registered in ClinicalTrials.gov with Meshalkin Research Institute of Pathology of Circulation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Randomised Controlled Study to Evaluate Outcomes of the Treatment With Pradaxa or Warfarin for Prevention of Recurrent VTE in Patients With Angiographically Confirmed Acute Massive Pulmonary Embolism Undergoing Endovascular Mechanical Fragmentation and Thrombolytic Therapy
- Lead sponsor
- Meshalkin Research Institute of Pathology of Circulation
- Phase
- Phase 4
- Overall status
- Unknown status
- Start date
- October 31, 2016
- Completion date
- June 30, 2018
- Enrollment
- 200 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
angiographically confirmed acute massive pulmonary embolism treated with endovascular mechanical fragmentation and thrombolytic therapy